Klaassen Zachary, Reinstatler Lael, Wilson Shenelle N, Ellington Chris, Li Qiang, Terris Martha K, Moses Kelvin A
Section of Urology, Department of Surgery, Medical College of Georgia - Georgia Regents University, Augusta, GA.
Section of Urology, Department of Surgery, Medical College of Georgia - Georgia Regents University, Augusta, GA.
Clin Genitourin Cancer. 2016 Jun;14(3):e251-5. doi: 10.1016/j.clgc.2015.08.004. Epub 2015 Sep 2.
Few reports have been published regarding the outcomes of patients who develop an undescended testicular malignancy (UTM). Our objective was to analyze the sociodemographic and survival outcomes of patients with UTM and those of with descended testicular malignancy (DTM).
All 17 registries constituting the Surveillance, Epidemiology, and End Results (SEER) database were analyzed from 1988 to 2008. Patients with a descended or undescended testis and a diagnosis of nonseminomatous or seminomatous testicular cancer were identified. Descriptive statistical data and multivariate analysis were used to identify the predictors of a UTM diagnosis. The primary outcomes were overall and disease-specific survival.
The study cohort included 10,159 men (95.3%) with DTM and 496 (4.7%) with UTM. Patients with UTM were more likely to be older, married, and a minority or foreign born and to have seminoma, a higher rate of node positivity, and a higher SEER stage compared with patients with DTM. The median survival time for patients with UTM was longer than that for patients with to DTM (83.1 vs. 72.5 months; P = .0001), although no difference was found in cancer-specific mortality (P = .34).
Patients with UTM are more likely to be a minority or foreign born, highlighting a previously unrecognized healthcare disparity that might represent a lack of diagnosis and access to care.
关于发生隐睾恶性肿瘤(UTM)患者的预后报道较少。我们的目的是分析UTM患者和下降型睾丸恶性肿瘤(DTM)患者的社会人口统计学特征和生存结果。
对1988年至2008年构成监测、流行病学和最终结果(SEER)数据库的所有17个登记处进行分析。确定患有下降型或未下降型睾丸以及诊断为非精原细胞瘤或精原细胞瘤性睾丸癌的患者。使用描述性统计数据和多变量分析来确定UTM诊断的预测因素。主要结局为总生存和疾病特异性生存。
研究队列包括10159例DTM男性患者(95.3%)和496例UTM男性患者(4.7%)。与DTM患者相比,UTM患者更可能年龄较大、已婚、属于少数族裔或外国出生,患有精原细胞瘤,淋巴结阳性率更高,SEER分期更高。UTM患者的中位生存时间长于DTM患者(83.1个月对72.5个月;P = .0001),尽管在癌症特异性死亡率方面未发现差异(P = .34)。
UTM患者更可能是少数族裔或外国出生,这凸显了一种先前未被认识到的医疗保健差异,可能代表着诊断和获得治疗方面的不足。